Teprasiran confers renoprotection in high-risk patients undergoing cardiac surgery
Treatment with the novel small interfering RNA teprasiran appears to cut the incidence, severity, and duration of early acute kidney injury (AKI) in high-risk patients undergoing cardiac surgery, according to the results of a phase II trial.
